Open access
Sep 2026
Survival Outcomes With Cadonilimab Versus PD‐(L)1 Therapy in Front‐Line Gastric Cancer: A Network Meta‐Analysis
The FDA Oncologic Drugs Advisory Committee (ODAC) highlighted that the risk–benefit profile for patients with low PD‐L1 expression remains unclear in front‐line treatment of HER2‐negative gastric and gastroesophageal junction (GC/GEJ) cancer with PD‐(L)1 therapy. The first PD‐1/CTLA‐4 bispecific antibody (BsAb), cadoni...
Zi-Kun Yu, Jia-Hong Yi, Ju Xue et al.
· Cancer Reports · 0 citations